New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 8, 2012
16:38 EDTBPAXBioSante reports Q3 EPS (27c), consensus (36c)
The decrease in the net loss was due primarily to lower clinical development expenses for LibiGel, its testosterone gel, during the most recent period as a result of the conclusion of all current LibiGel clinical studies.
News For BPAX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for BPAX

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use